Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04402840 · ClinicalTrials.gov registry record · NA
Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
A NA study, sponsored by West Virginia University.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT04402840: Completed NA study, sponsored by West Virginia University.
NCT04402840 is a NA study that has completed, run by West Virginia University. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04402840, a NA study, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.
Primary Outcome
Adverse events that can atleast unlikely be attributed to SGB
Interventions
- PROCEDURE Stellate Ganglion Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2020-12-31 |
| Phase | NA |
What the finished NCT04402840 record still lists
NCT04402840 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Stellate Ganglion Block is the first listed.
NCT04402840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04402840 about?
NCT04402840 is a clinical study titled "Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)". The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.
What is the current status of trial NCT04402840?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2020-04-24. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04402840?
The interventions under investigation include: Stellate Ganglion Block (PROCEDURE).
Who is sponsoring clinical trial NCT04402840?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04402840's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI